Growth factors and tumor promoters have been shown to play a role in intestinal epithelial growth regulation and transformation. In this study, transforming growth factor-a (TGFa) and the tumor promoter, tetradecanoyl phorbol acetate (TPA), are shown to stimulate the production of eicosanoids by rat intestinal epithelial (RIE-1) cells in culture. A 4.5-kb mRNA, which hybridizes to the mouse cyclooxygenase-2 cDNA probe, is elevated 18-fold within 30 min after TGFa or TPA treatment. Stimulation of RIE-1 cells with TGFa leads to the increase of a protein (Mr -69,000), which binds a monospecific antibody to the mouse cyclooxygenase-2 protein. Dexamethasone markedly inhibits the increase of the 4.5-kb mRNA. Pretreatment of TGFa or TPA-stimulated RIE-1 cells with dexamethasone or cyclooxygenase inhibitors prevents the increase in eicosanoid production by these cells. Treatment of quiescent RIE-1 cells with TGFa stimulates mitogenesis. This mitogenic activity is blocked by pretreating the cells with dexamethasone or cyclooxygenase inhibitors. A mitogen-inducible cyclooxygenase gene is thus shown to be regulated by TGFa and TPA in rat intestinal epithelial cells. We suggest that products of an intestinal growth factor-inducible cyclooxygenase may play a role in the regulation of mitogenesis. (J. Clin. Invest. 1994. 93:493498.)
Introduction
Cyclooxygenase (COX) ' is a key enzyme in the conversion of arachidonic acid to prostanoids. Recent clinical studies indicate that cyclooxygenase inhibitors may affect intestinal polyp formation and/or the development of colon cancer in humans (1) (2) (3) (4) (5) (6) . One study convincingly demonstrated that colon polyp size and number decreased dramatically in familial adenomatous polyposis patients treated with sulindac, a pro-drug that is converted to a cyclooxygenase inhibitor in the colon, (5) . Fa-milial adenomatous polyposis is an autosomal dominant disorder in which virtually all of those affected will develop colorectal cancer by the fifth decade of life if untreated (7) . In epidemiologic studies, cyclooxygenase inhibitors (like aspirin) have been shown to decrease the relative rate of colon cancer by -40-50% in humans (1) (2) (3) (4) . The mechanism by which cyclooxygenase inhibitors cause either polyp regression or lower the relative rate of colon cancer is unknown. The precise relationship between eicosanoid metabolism, intestinal epithelial growth regulation, and carcinogenesis is presently an area of active investigation (2) .
One of the immediate early genes, which has been cloned from stimulated mouse fibroblasts, encodes a protein with remarkable homology to prostaglandin G/H synthase (PGHS; 8,11,1 4-icosatrienoate-hydrogen-donor/ oxygen oxidoreductase, EC 1.14.99.1 ) or cyclooxygenase. This immediate early gene has been referred to by the following designations: TIS 10 (8), PGHS 11 (9) , COX-2 (10), griPGHS (11) , and pghsB (12) . "Immediate early" or "early growth response" genes comprise a diverse group of genes whose expression rapidly increases in response to growth stimulation in a number of biological systems (13) (14) (15) (16) . These genes encode polypeptides with a variety of functions, including nuclear transcription factors, cytoplasmic enzymes, membrane proteins, and cytokines. They are induced within 30 min after serum or growth factor treatment ofquiescent cells in culture, and the increase in their mRNA levels is independent of new protein synthesis. Due to their dramatic induction after growth stimulation, it has been assumed that this group of genes plays a role in the regulation of cell growth. Some of the immediate early transcription factors (c-fos and c-jun) have been shown directly to play an important role in growth regulation (17) (18) (19) .
In this study, we report the regulation ofan intestinal epithelial cyclooxygenase gene by TGFa and TPA. TGFa is a member ofthe epidermal growth factor family ofmitogens and associated with progression of transformed properties in human colon cancer cells (20) . Rat intestinal epithelial (RIE-1) cells were derived from intestine, established in culture, and initially characterized by Blay and Brown (21) . These cells, which are nontransformed, maintain epithelial cell markers, and are mitogenically responsive to EGF (21, 22) and TGFa (22) in culture. We have recently shown that treatment ofthese cells with TGFa causes a dramatic induction ofseveral immediate early genes at the transcriptional level (22) . Here we demonstrate that the COX-2 enzyme is induced and eicosanoid production increased after TGFa or TPA treatment of RIE-1 cells. Addition of a potent cyclooxygenase inhibitor (sulindac sulfide) or glucocorticoids (dexamethasone) before growth factor treatment inhibits the incorporation of [3H]thymidine into DNA during S phase. This work represents the first report of the presence of the COX-2 pathway in rat intestinal epithelial cells and of agonist-mediated regulation at the level of mRNA expression, protein production, and eicosanoid product forma-tion. However, the COX-2 protein is present in cultured tracheal epithelial cells (23) . In human clinical studies, cyclooxygenase inhibitors have been shown to decrease polyp number, size, and the incidence ofcolon cancer. The precise mechanism for these clinical findings remains unknown. The studies reported here demonstrate that this pathway ofeicosanoid metabolism (COX-2) needs to be considered in future research designed to evaluate the molecular basis for the development of colonic adenomas in humans.
Methods
Cell culture, RNA isolation, and Northern blot analysis. RIE-l cells were a gift from Ken Brown (Cambridge Research Station, Babraham, Cambridge, UK). Cells were grown in DME supplemented with 10% FBS (Lot No. 11151032; Hyclone Laboratories, Logan, UT), 2 mM L-glutamine, 100,000 U/liter penicillin G. and 100,000 ,gg/liter streptomycin sulfate. Cells were carried for no more than 10 passages, and for all experiments 70-95% confluent cultures were rendered quiescent by incubating in serum-free DME for 72 hours before growth stimulation. Messenger RNA was isolated from RIE-I cells as described (24) using type 3 oligo-d(T) cellulose (Collaborative Research, Inc., Bedford, MA). RNA samples were electrophoresed in denaturing agarose gels and transferred to nitrocellulose. Nitrocellulose blots were hybridized using conditions previously described (25) (26) . Western blotting was carried out as described (27) , with the following modifications. Microsomal proteins were resuspended into a 10 mM Tris-HCl buffer, pH 7.5, using a glass Teflon homogenizer (Wheaton, Millville, NJ). Protein concentrations were determined using an assay (BioRad Laboratories, Hercules, CA), equivalent amounts of protein were electrophoresed by discontinuous SDS-PAGE (28) , and the proteins were electrophoretically transferred to nitrocellulose filters (Transblot; BioRad Laboratories). After transfer, the filters were incubated in a blocking solution (10 mM Tris-HCl, 150 mM NaCl, 5% BSA, pH 7.4) for 30 min at 40°C and then incubated with a primary rabbit anti-mouse COX-2 antibody (Oxford Biomed Res, Inc.). The filters were washed three times in washing solution (10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.4) and incubated with the secondary goat antirabbit IgG alkaline phosphatase conjugated antibody (Promega Corp). After washing three times as before, the filters were incubated in a solution containing substrate for the alkaline phosphatase enzyme as described (25 (Fig. 2) . When similar immunoblots were probed with a monospecific COX-1 antibody, no immunostaining was detected (data not shown). This experiment confirms the selective mitogen-dependent induction of the COX-2 enzyme in the RIE-cells.
TGFa regulation ofeicosanoidproduction. After treatment of RIE-1 cells with TGFa or TPA, prostacyclin (PGI2), measured as its nonenzymatic hydrolysis product, 6-keto-prostaglandin (PG)Fa (6-keto-PGFia), was the predominant prostanoid present (Fig. 3) . We observed a fourfold stimulation of 6-keto-PGFia within 4 h after growth factor treatment and a 16-fold stimulation by TPA treatment during that same time period. In addition, PGD2, PGE2, TxB2, and PGF2,, production was increased following growth factor or phorbol ester treatment, albeit to a lesser extent than 6-keto-PGFIa. This experiment demonstrates that the RIE-1 cells are capable of growth-factor-regulated prostanoid synthesis, with 6-ketoPGFIa increased by fourfold 4 h after TGFa treatment and 16-fold 4 h after TPA treatment. Our finding that PGI2 is the predominant prostanoid produced by intestinal epithelial cells is consistent with in vivo studies reported by Needleman and others (30, 31 ) . At various times after TGFa treatment, the cell medium was collected and 6-keto-PGFia was measured.
We have carried out these incubations both in the absence (data not shown) and presence ofexogenous arachidonic acid. We observed the same fold increase in PG synthesis in both cases, although the relative level of prostanoid produced was decreased in the absence of exogenous substrate. As shown in Fig. 4 , there was a significant increase in 6-keto-PGF1a level within 2 h after growth factor treatment. This continued to increase until 8 h, at which time the level was -20-fold higher than the untreated controls. The level of 6-keto-PGF1,, decreased significantly by the 24-h time point. This experiment demonstrates that in addition to induction of COX-2 mRNA and protein, we also observed a marked time-dependent increase in the production of cyclooxygenase products as a result of growth factor treatment.
Inhibition ofCOX-2 mRNA induction, increase in cyclooxygenase activity, and mitogenesis by glucocorticoids. Other investigators (32) have shown that dexamethasone inhibits the induction of COX-2 mRNA. Therefore, we treated cells with dexamethasone before growth factor or TPA stimulation. The result of this experiment (Fig. 5 A) demonstrates that the induction ofthe COX-2 mRNA is markedly inhibited bytreating the cells with dexamethasone before adding the growth factor or tumor promoter. To determine if this inhibition was reflected by a decrease in cyclooxygenase activity after growth stimulation, we measured 6-keto-PGF1a production in the presence and absence of dexamethasone. The results, demonstrated in Fig. 5 B, indicate that dexamethasone pretreatment completely inhibited the increase in 6-keto-PGFia formation after TGFa or TPA treatment. To determine if glucocorticoid treatment had any effect on TGFa-stimulated mitogenesis, we treated the RIE-1 cells with 1 ,uM dexamethasone before addition of TGFa to the cell culture medium. The data shown in ited the increase in COX-2 mRNA and prostanoid production but also dramatically inhibited mitogenesis after TGFa treatment.
Inhibition ofcyclooxygenase activity and TGFa-stimulated mitogenesis by sulindac sulfide and indomethacin. We treated the RIE-1 cells with various concentrations of two known cyclooxygenase inhibitors (sulindac sulfide and indomethacin) before addition ofgrowth factor to the cell culture medium. As shown in Fig. 6 A, the addition of cyclooxygenase inhibitors markedly decreases prostanoid production. To determine ifthe inhibition ofcyclooxygenase activity had an effect on mitogenesis, we measured [3H]thymidine incorporation into DNA after TGFa treatment in the presence ofcyclooxygenase inhibitor. The data shown in Fig. 6 B demonstrate that addition of cyclooxygenase inhibitors markedly inhibits the incorporation of [3H]thymidine into DNA at 18 h after growth factor treatment. We found that sulindac sulfide was slightly more effective than indomethacin in inhibiting mitogenesis. These experiments indicate that, in addition to inhibiting prostanoid production, sulindac sulfide and indomethacin inhibit mitogenesis in the RIE-1 cells.
Discussion
In this report we demonstrate that a mitogen-inducible cyclooxygenase mRNA is elevated within 30 min and the level reaches 2 1-fold above controls within 1 h after growth stimulation of RIE-1 cells in culture. We have chosen to study the effects of TGFa on this pathway, since it is a potent epithelial mitogen and has been shown to be associated with progression of transformation in human colon cancer cells. We observed a fourfold increase in 6-keto-PGFia production within 4 h and a 16-fold increase 8 h after TGFa treatment. TPA alone caused -10-fold increase in 6-keto-PGFI, production at 4 h after treatment. Since TPA was four times more effective than TGFa in stimulating eicosanoid production, it seems likely that signaling through a protein kinase C pathway is involved in the activation of eicosanoid production in RIE-1 cells, and that signaling through this pathway can achieve a greater stimulation of eicosanoid production at the 4-h time point. In addition, treatment of these cells with TGFa results in a dramatic increase in the level of a protein (Mr -69,000), which immunoreacts with a monospecific COX-2 antibody on Western blots.
Sulindac is a pro-drug, which is converted in the liver and colon to the sulfide by reversible reduction (33) . Sulindac sulfide and indomethacin appear indistinguishable in their ability to inhibit COX-1. Pretreatment of stimulated RIE-1 cells with sulindac sulfide or dexamethasone not only inhibits the induction of 6-keto-PGFia production, but also inhibits the mitogenic response of these cells to TGFa. From these results, it seems plausible to consider the possibility that the mitogen-inducible cyclooxygenase may produce certain eicosanoids that play a role in growth regulation of intestinal epithelial cells. Inhibition of cyclooxygenase enzyme activity or prevention of its induction can modulate the proliferation ofthese cells. Obviously, the dexamethasone effect will require more experimentation to understand completely because it has been shown to prevent the induction of other immediate early genes in fibroblasts (34) . It is of interest to note that the morphology ofneu-, ras-, src-, and sis-transformed mouse fibroblasts became more normal after glucocorticoid treatment (35) . Clearly, further investigation will be required to determine the precise role (if any) of COX-2 in the regulation of intestinal epithelial growth. The COX-2 gene isolated from murine cDNA libraries (8-12) encodes a protein that shares only -42% amino acid sequence identity with COX-1 at the amino terminal region ( 102 amino acids from the start methionine); whereas, the amino acid identity over the rest of the protein is -66%. The COX-2 enzyme has been shown to have an altered sensitivity to cyclooxygenase inhibitors (36) . If the mitogen-inducible COX-2 enzyme is proven to play a role in growth regulation, then the availability of selective inhibitors will be important for clinical applications. If drugs are identified that inhibit the COX-2 enzyme preferentially, they may be efficacious in human colon cancer chemoprevention trials (5) .
Work is currently underway to clone and characterize the rat and human intestinal mitogen-stimulated cyclooxygenase genes and evaluate the activity ofthe enzymes they encode with respect to substrate specificity and susceptibility to inhibition by known cyclooxygenase inhibitors. One group has recently cloned the genomic 5' flanking sequence of the rat COX-2 gene, but to date the cDNA and/or coding sequence for this gene has not been reported (37) . Note added in proof: Since submission otthis manuscript the rat COX-
